Patents by Inventor Michael Anthony Hollingsworth

Michael Anthony Hollingsworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of targeting glycoproteins to treat cancer
    Patent number: 10023652
    Abstract: The present disclosure relates to a method of inhibiting tumor growth. More specifically, the present disclosure relates to the use of monoclonal antibodies for targeting truncated O-glycans on glycoproteins to inhibit activation of pro-survival ceil signaling pathways, to inhibit tumor growth. For example, monoclonal antibody AR9.6 may be used to target truncated O-glycans on the MUC16 glycoprotein, thereby inhibiting the phosphatidyiinositol 3-kinase/Akt (Pi3K/Akt) signaling pathway.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: July 17, 2018
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Michael Anthony Hollingsworth, Prakash Radhakrishnan
  • Novel Method of Targeting Glycoproteins to Treat Cancer
    Publication number: 20160376376
    Abstract: The present disclosure relates to a method of inhibiting tumor growth. More specifically, the present disclosure relates to the use of monoclonal antibodies for targeting truncated O-glycans on glycoproteins to inhibit activation of pro-survival ceil signaling pathways, to inhibit tumor growth. For example, monoclonal antibody AR9.6 may be used to target truncated O-glycans on the MUC16 glycoprotein, thereby inhibiting the phosphatidyiinositol 3-kinase/Akt (Pi3K/Akt) signaling pathway.
    Type: Application
    Filed: June 24, 2014
    Publication date: December 29, 2016
    Inventors: Michael Anthony Hollingsworth, Prakash Radhakrishnan
  • Compositions and methods for preventing or treating cancer
    Patent number: 8653233
    Abstract: The present invention relates to a MUC1 cytoplasmic tail peptide or portion thereof. These peptides are useful for inducing an immune response to MUC1-expressing tumor cells and thus for preventing or treating cancer.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: February 18, 2014
    Assignee: University of Nebraska Medical Center
    Inventors: Michael Anthony Hollingsworth, Karl Kohlgraf, Tom Caffrey
  • Compositions and Methods for Preventing or Treating Cancer
    Publication number: 20120270798
    Abstract: The present invention relates to a MUC1 cytoplasmic tail peptide or portion thereof. These peptides are useful for inducing an immune response to MUC1-expressing tumor cells and thus for preventing or treating cancer.
    Type: Application
    Filed: June 1, 2012
    Publication date: October 25, 2012
    Inventors: Michael Anthony Hollingsworth, Karl Kohlgraf, Tom Caffrey
  • Compositions and methods for preventing or treating cancer
    Patent number: 8193309
    Abstract: The present invention relates to a MUC1 cytoplasmic tail peptide or portion thereof. These peptides are useful for inducing an immune response to MUC1-expressing tumor cells and thus for preventing or treating cancer.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: June 5, 2012
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Michael Anthony Hollingsworth, Karl Kohlgraf, Tom Caffrey
  • Compositions and Methods for Preventing or Treating Cancer
    Publication number: 20100190720
    Abstract: The present invention relates to a MUC1 cytoplasmic tail peptide or portion thereof. These peptides are useful for inducing an immune response to MUC1-expressing tumor cells and thus for preventing or treating cancer.
    Type: Application
    Filed: January 29, 2010
    Publication date: July 29, 2010
    Inventors: Michael Anthony Hollingsworth, Karl Kohlgraf, Tom Caffrey